Clinical trials: in India
Metastatic Castration-Sensitive Prostate Cancer
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants…
- Trial name
- EvoPAR-PR01 (NCT06120491)
- Testing
- Saruparib, Abiraterone Acetate, Darolutamide
- Where
- 322 sites in United States, Australia and 22 more
- Volunteers
- 1,898 people
- Sponsor
- AstraZeneca
Functioanl Dyspepsia
Vonoprazan Alone vs With Itopride for Functional Dyspepsia: The VIVA Trial
The VIVA trial is a 12-week, randomized, interventional study comparing vonoprazan monotherapy versus vonoprazan plus itopride combination therapy in adults with functional dyspepsia (FD).
- Trial name
- NCT07731542
- Testing
- Vonoprazan plus Itopride combination, Vonoprazan
- Where
- India
- Volunteers
- 192 people
- Sponsor
- Asian Institute of Gastroenterology, India
Gram-negative Bacteremia, Bloodstream Infection
Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial
This study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized 1:1 to have the positive…
- Trial name
- FAST (NCT06174649)
- Testing
- Reveal
- Where
- 7 sites in Greece, India and 2 more
- Volunteers
- 899 people
- Sponsor
- Duke University
Reversible Pulpitis, Deep Caries
Comparative Evaluation of Direct Pulp Capping Between Deep and Extremely Deep Caries in Mature Permanent Mandibular Molars .
The aim of the study is to compare the clinical and radiographic outcomes of direct pulp capping for deep and extremely deep caries in mature permanent mandibular molars with reversible pulpitis.
- Conditions
- Reversible Pulpitis, Deep Caries, Extremely Deep Caries
- Trial name
- NCT07696702
- Testing
- Direct pulp capping in extremely deep carious lesion., Direct pulp capping in deep carious lesion.
- Where
- India
- Volunteers
- 130 people
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Septic Shock, Disseminated Intravascular Coagulation
Disseminated Intravascular Coagulation (DIC) Score and Organ Dysfunction in Septic Shock Patients
Septic shock is common complication in patients with critical illnesses, with higher incidence in low and medium income countries like ours.
- Trial name
- NCT06363149
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Advanced Solid Tumors
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country.
- Trial name
- NCT07042100
- Testing
- Dose level (DL)1, DL2, DL3
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 177 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Stomach Neuroendocrine Neoplasm
Safety and Efficacy of Underwater Endoscopic Mucosal Resection for Type I Gastric Neuroendocrine Tumors Measuring 5-9 mm
Study objectives: Primary objective: 1.To determine the histologic R0 resection rate of UEMR for type I gastric NETs measuring 5-9 mm. Secondary objectives: To evaluate: 1. En bloc resection rate 2.
- Trial name
- POEM (NCT07728292)
- Testing
- Endoscopic mucosal resection under water
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Asian Institute of Gastroenterology, India
Oral Mucositis, Total Body Irradiation
Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant
The goal of this phase II, single-arm interventional clinical trial is to evaluate whether oral sodium copper chlorophyllin (CHL) can reduce the frequency and severity of oral mucositis in patients aged 12-65 years undergoing…
- Conditions
- Oral Mucositis, Total Body Irradiation, Hematological Malignancies, Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- ChROMME-TBI (NCT07709195)
- Testing
- Sodium Copper Chlorophyllin
- Where
- India
- Volunteers
- 17 people
- Sponsor
- Tata Memorial Centre
Rheumatoid Arthritis
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the parent studies of filgotinib in rheumatoid arthritis (RA).
- Trial name
- FINCH 4 (NCT03025308)
- Testing
- Filgotinib
- Where
- 345 sites in United States, Argentina and 30 more
- Volunteers
- 2,731 people
- Sponsor
- Alfasigma S.p.A.
Intraductal Papillary Mucinous Neoplasm
Intra-operative Pancreatoscopy in Patients With IPMN
To demonstrate the added value of intraoperative pancreatoscopy in patients undergoing partial pancreatic resection for the treatment of Intraductal Papillary Mucinous Neoplasm (IPMN) as it pertains to detection of discontinuous…
- Trial name
- NCT03729453
- Testing
- SpyGlass
- Where
- 8 sites in United States, China and 4 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of…
- Trial name
- MIRANDA (NCT06040086)
- Testing
- Tozorakimab
- Where
- 368 sites in United States, Argentina and 27 more
- Volunteers
- 1,454 people
- Sponsor
- AstraZeneca
Bipolar Disorder, Manic
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with…
- Trial name
- NCT06462586
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 354 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease
Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients
What is acute Graft versus host disease (aGvHD)? GvHD is a complication that can occur after an allogeneic stem cell transplant resulting in damage to some organs. The death rate of GvHD patients is 15-40%.
- Conditions
- Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease, Hematological Malignancy
- Trial name
- NCT07724873
- Testing
- SWA (standardized root extract of Withania somnifera)
- Where
- 2 sites in India
- Volunteers
- 54 people
- Sponsor
- Tata Memorial Centre
Health Care Utilization, Health Care Seeking Behavior
Arogya Sangama: 3 Way Partnership of People, Providers, and Panchayat for Health
This is a two-year pilot project in the Raichur and Chamarajanagar districts of Karnataka, India aiming to enhance the overall performance of primary health systems, including service utilization, quality, and responsive care…
- Conditions
- Health Care Utilization, Health Care Seeking Behavior, Health Knowledge, Attitudes, Practice
- Trial name
- NCT06224712
- Testing
- Arogya Sangama
- Where
- 2 sites in India
- Volunteers
- 4,160 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Breast Neoplasms, Neoplasm Metastasis
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is…
- Trial name
- EMBER-3 (NCT04975308)
- Testing
- Imlunestrant, Exemestane, Fulvestrant
- Where
- 243 sites in United States, Argentina and 20 more
- Volunteers
- 874 people
- Sponsor
- Eli Lilly and Company
IBS (Irritable Bowel Syndrome)
Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms
A randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy of two different mixes of HMO-2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB) on Gastrointestinal Symptoms in…
- Trial name
- DORPHI (NCT06889779)
- Testing
- MIX 1, MIX 2
- Where
- 12 sites in India
- Volunteers
- 353 people
- Sponsor
- dsm-firmenich Switzerland AG
High-risk Muscle Invasive Urothelial Carcinoma
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection.
- Trial name
- TU-04 (NCT07720284)
- Testing
- Dato-DXd, Rilvegostomig, Durvalumab
- Where
- 160 sites in United States, Australia and 14 more
- Volunteers
- 915 people
- Sponsor
- AstraZeneca
Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies
To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers
Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant.
- Trial name
- NCT07719946
- Testing
- Cyclophosphamide
- Where
- 2 sites in India
- Volunteers
- 20 people
- Sponsor
- Tata Memorial Centre
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose…
- Trial name
- COAST 1 (NCT06130566)
- Testing
- Amlitelimab
- Where
- 148 sites in United States, Argentina and 13 more
- Volunteers
- 601 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.